Zacks.com on MSN2d
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest ...
Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on ...
A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...
Would you like to be notified of the latest news and updates on the stock market?
Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...
Reports Q4 revenue $200.7M, consensus $202.8M. “Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to ...
Tempus AI Inc (TEM) reports impressive revenue growth, strategic acquisitions, and extended partnerships, setting the stage for a promising 2025.
Tempus posted a fourth-quarter adjusted net loss of $0.18 per share, $0.02 more per share than estimates by analysts surveyed by Visible Alpha. Revenue jumped 36% year-over-year to $200.7 million, but ...
CHICAGO - Tempus AI , Inc. (NASDAQ:TEM ... Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.
We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback